The diminished cellular levels of RasGRF2 in AnxA6 expressing cells and the associated decrease in the activation of Ras and ERK1/2 as well as reduced tumor growth are consistent with the inhibition of the growth of AnxA6 expressing tumor cells. The gene discussed is MAPK3; the disease is neoplasm.